Tazverik (tazemetostat)

A cancer cell membrane (CCm)-camouflaged nanoplatform (CCm-HSA-Taz) was engineered to encapsulate the EZH2 inhibitor Tazemetostat (Taz), enabling tumor-targeted delivery...Nuclear medicine imaging revealed reduced tumor glucose metabolism and improved immune cell cytotoxicity. Utilizing components approved by the FDA suggests the potential for this strategy to be translated into clinical settings.

Moreover, we observed changes in the EV cargo derived from EZH2 inhibitor-treated spheroids. Our findings highlight the significant role of EVs in creating an immunosuppressive microenvironment, and underscore the urgent need for further investigation into the regulation of neutrophil biology and function in the PM.

The ancillary testing of SMARCB1 (INI-1) should be considered in a subset of patients whose tumor demonstrates bizarre cytomorphology, especially in poorly differentiated or markedly pleomorphic tumors. The cytological recognition is critical for appropriate management.

This leads to increased levels of Matrix metalloproteinase-9 (MMP-9) and vimentin, enhancing the invasion, migration, and metastasis of hepatocellular carcinoma (HCC) cells. However, inhibiting EZH2 with tazemetostat subsequently enhanced claudin-4 expression by reducing Wnt/β-catenin signaling activity and inhibiting EMT-inducing factors.

P1/2, N=58, Completed, Epizyme, Inc. | Active, not recruiting --> Completed

This work characterizes at a single-cell level the Enzalutamide resistant clone and the impact of epigenetic inhibitors on resistance development. This characterization may enable the identification of resistant and non-resistant cells by their gene expression profile.

P=N/A, N=10, Not yet recruiting, Shunyi Women's & Children's Hospital of Beijing Children's Hospital; Shunyi Women's & Children's Hospital of Beijing Children's Hospital

P=N/A, N=10, Not yet recruiting, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health; Beijing Children's Hospital, Capital Medical Universit

P=N/A, N=10, Recruiting, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health; Beijing Children's Hospital, Capital Medical Universit

EZH2 (Dznep; tazemetostat), PI3K, and AKT inhibitors were tested in combination with afatinib. EZH2-driven PTEN suppression promotes AKT-dependent afatinib resistance in radiation-resistant cervical cancer. Targeting the EZH2-PTEN-AKT axis may provide a potential therapeutic approach to mitigate combined radioresistance and chemoresistance in recurrent cervical cancer, although further preclinical and clinical validation is required.

Pharmacological inhibition of EZH2 with EPZ6438 reactivated TDG expression in RAS and BRAF-mutated ATC cell lines and partially restored iodide uptake...Impact statement This study reveals how EZH2-driven epigenetic remodeling controls thyroid cell dedifferentiation and loss of iodide uptake in anaplastic thyroid cancer. Our findings provide new mechanistic insights and highlight an FDA-approved drug with repurposing potential, advancing both anaplastic thyroid cancer biology research and therapeutic perspectives.